TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism
Brief Summary: The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.


Options:
A: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy (Baseline, within 48 +/- 6 hours of initiation of therapy); Number of Participants With Major Bleeding (From start of study drug infusion up to 72 hours)
B: at 3 months, combined criteria including recurrent PE confirmed by objective tests and fatal PE confirmed by autopsy and death which can not be attribuated to a documented cause and for which PE/DVT can't be ruled out (3 months)
C: Exercise Limitation (1 month); Exercise Limitation (12 months)
D: Reduction of RV/LV Ratio (24 hours); Major Bleeding and Intracranial Bleeding at 30 Days. (30 days)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: Child BMI
B: Proportion of small consumers of fruits and vegetables among children (12 months)
C: Change in vegetable intake (Measured at child age of 4-6 months (prior to intervention), 18 months (directly after intervention) and at child age of 24 and 36 months (6 and 18 months follow-up)); Change in vegetable liking (Measured at child age of 4-6 months (prior to intervention), 18 months (directly after intervention) and at child age of 24 and 36 months (6 and 18 months follow-up)); Child self-regulation of energy intake (Measured at child age of 18 months); Change in child self-regulation of energy intake (Measured at child age of 4-6 months (prior to intervention), 18 months (directly after intervention) and at child age of 24 and 36 months (6 and 18 months follow-up))
D: BMI percentile at 3 years (3 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: BMI percentile at 3 years (3 years)
B: Change in Children´s Consumption of Foods From Baseline to 3 Months by Intervention Assignment (0, 3 months); Change in Children´s Time of Physical Activity From Baseline to 3 Months by Intervention Assignment (0, 3 months); Change in Score z of Body Mass Index From Baseline to 3 Months by Intervention Assignment (0, 3 month)
C: fasting blood glucose (Baseline to 10 months postpartum); weight (body mass index) (Baseline to 10 months postpartum)
D: Vegetable Intake in Preschool Children (1 year 11 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: BMI z score (24 months (end of intervention)); BMI z score (60 months of age (followup at 5 years of age)); BMI z score (Follow-up at 11 years of age)
B: Intake of nutrients; Serum lipid and lipoprotein concentrations; Growth and development; Smoking; Physical activity level and fitness; Intima-media thickness of arteries and rate of NO-induced vasodilatation
C: Change in intake of the target vegetable (Change in intake of the target vegetable from Baseline to day 14)
D: BMI percentile at 3 years (3 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: BMI percentile at 3 years (3 years)
B: Change in child adiposity from baseline measured via BMI z-score (Enrollment, 6 months, 12 months, 18 months, 24 months); Change in adult adiposity from baseline measured via BMI (Enrollment, 12 months, 24 months)
C: Percent of children overweight or obese (BMI ≥ 85th%) at 2 years of life (2 years)
D: body mass index (three years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: Frequency of exclusive and total breastfeeding (First year)
B: Change in fruits and vegetables and dairy products (Before and after the intervention (0 and 6 wk))
C: BMI percentile at 3 years (3 years)
D: Body Mass Index (one year)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: Infant length at 18 months (18 months of age. Protocol and Statistical Analysis Plan are available at https://osf.io/w93hy.); Infant hemoglobin at 18 months (18 months)
B: N/A
C: HIV infection detected by 4 months among children with no evidence of HIV infection at birth. (24 months of age); Magnitude of the reduction in mother-to-child HIV transmission and the magnitude of the increase in non-HIV-related under-2-year mortality, attributable to cessation of breastfeeding at 4 months.
D: BMI percentile at 3 years (3 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: BMI percentile at 3 years (3 years)
B: Number of parents engaging with the HENRY programme measured using Centre level process data (12 month post randomisation (allowing 3 months for Optimisation intervention implementation and collecting data from 1- 2 HENRY courses per site).)
C: Child BMI
D: Change from baseline in energy dense food consumption at 12 months (12 months); Change from baseline in nutrient dense food consumption at 12 months (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Cybercycling for Older Adults: Neuropsychological, Physiological and Behavioral Effects
Brief Summary: Exercise has been linked to cognitive health, but few older adults exercise at recommended levels. Cybercycling may provide additional cognitive benefits due to increased motivation to ride the interactive 3D tours. Participants will be randomly assigned to three months of either cybercycling or traditional stationary biking; and they will complete comprehensive evaluations before and after exercise. Older adults are expected to show significant neuropsychological, physiological and behavioral gains.


Options:
A: Changes in Global Cognition (Both, the pre- and the post-measurements of the primary outcome measurement will take place within two weeks prior to starting or after completing the intervention.)
B: Falls rate (6 months post intervention)
C: Change in cognitive function after three months of exercise. (3 months)
D: MoCA (2 years); SPPB (2 years); NPI (2 years); CSDD (2 years); DQOL (2 years); (I)ADL (2 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Postoperative Functional mobility; Restricting factors for functional mobility
B: Total Number of Units Transfused (From randomization until discharge from admission for delivery, an average of 2-3 days)
C: Physical Fatigue (on day 3 postpartum)
D: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)
B: Amount of FFP (Fresh Frozen Plasma) transfusion in both groups (42 days)
C: Randomization Rate (12 months)
D: Postoperative Functional mobility; Restricting factors for functional mobility

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)
B: Primary outcomes are related to feasibility and include recruitment rate, protocol adherence & difference in mean Hb concentration and RBC exposure between the 2 groups. (60 days following randomisation)
C: Recruitment: screening (One year); Recruitment: consent (One year); Recruitment: enrolment (One year)
D: Quality of Life (QOL)/Function based on the FACT-BMT scale (3 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)
B: number of patients receiving the transfusion of at least one unit of allogeneic red blood cell (between the begining of surgery (day 1) and the eighth post-operative day (day 8))
C: Mortality at the 45th day (45 days)
D: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death (60 days after randomization)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Quality of Life (QOL)/Function based on the FACT-BMT scale (3 years)
B: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)
C: Timed Up and Go-test (TUG)in seconds. (30 days)
D: The primary purpose of this study is to compare clinical outcomes after cardiac surgery in patients submitted to different strategies of red blood cell transfusion (30 days after surgery)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization. (90 days after randomization)
B: Cost-effectiveness ratio at 30 days (30 days)
C: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)
D: Composite score of any one of the following: (1) all-cause mortality; (2) myocardial infarction; (3) new renal failure requiring dialysis; or (4) new focal neurological deficit (Up to hospital discharge or postoperative day 28 (whichever occurs first))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Glasgow Outcome Scale (at 6 months after injury)
B: The primary purpose of this study is to compare clinical outcomes after cardiac surgery in patients submitted to different strategies of red blood cell transfusion (30 days after surgery)
C: Adherence to the study protocol (up to 28 days)
D: Hemoglobin Concentration (In-hospital up to 30 days post randomization); Red Blood Cell Transfusion (In-hospital up to 30 days post randomization)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Brief Summary: This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.


Options:
A: N/A
B: Treatment success.Treatment success is defined as the ability to deliver 6 courses of chemotherapy without premature termination for progression, death or unacceptable toxicity (After 6 courses of chemotherapy i.e 4.5 to 6 months (depending on the arm))
C: Progression Free Survival (Up to 34 months)
D: Progression-Free Survival (The timeframe is from enrollment onto the study up to 3 years following enrollment.)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Brief Summary: This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.


Options:
A: Objective Response Rate (ORR) (RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months))
B: Progression-Free Survival (The timeframe is from enrollment onto the study up to 3 years following enrollment.)
C: Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort (From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)); Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population (From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months))
D: Progression-free Survival According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (From baseline up to disease progression or death within 30 days of last study drug administration (overall up to approximately 2.5 years))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Brief Summary: This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.


Options:
A: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) (Radiologic scans performed at baseline then every 12 weeks (+/- 1 week) for the first 60 weeks, then every 24 weeks (+/-1 week) thereafter, assessed maximum up to 14 months.)
B: Progression-free Survival (Baseline to the data cut-off date of 19 Jul 2012 for analysis of the primary Outcome Measure (follow-up time up to 3 years, 1 month))
C: Progression-Free Survival (PFS): Independent Radiologist Review (From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years)
D: Progression-Free Survival (The timeframe is from enrollment onto the study up to 3 years following enrollment.)

Answer: D